


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (previously presented) A compound of the Formula A:



wherein:

a is 0 or 1; b is 0 or 1; m is 0, 1 or 2; n is 0, 1, 2 or 3; p is 0, 1 or 2; q is 0, 1, 2 or 3; r is 0 or 1; s is 0 or 1; t is 2, 3, 4, 5 or 6;



is heterocyclyl;

Q is pyrimidinyl pyrazole optionally substituted with one to three R^Z;

R¹ is independently selected from: 1) (C=O)_aO_bC₁-C₁₀ alkyl, 2) (C=O)_aO_baryl, 3) C₂-C₁₀ alkenyl, 4) C₂-C₁₀ alkynyl, 5) (C=O)_aO_b heterocyclyl, 6) (C=O)_aO_bC₃-C₈ cycloalkyl, 7) CO₂H, 8) halo, 9) CN, 10) OH, 11) O_bC₁-C₆ perfluoroalkyl, 12) O_a(C=O)_bNR⁶R⁷, 13) NR^c(C=O)_bNR⁶R⁷, 14) S(O)_mR^a, 15) S(O)₂NR⁶R⁷, 16) NR^cS(O)_mR^a, 17) oxo, 18) CHO, 19) NO₂, 20) NR^c(C=O)O_bR^a, 21) O(C=O)O_bC₁-C₁₀ alkyl, 22) O(C=O)O_bC₃-C₈ cycloalkyl, 23) O(C=O)O_baryl, 24) C₁-C₆alkyl(C=NR^b)N(R^b)₂, 25) O(C=O)O_b-heterocycle, 26) O_a-P=O(OH)₂ and 27) -N=CHN(R^b)₂, said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R^Z;

R² is independently selected from: 1) (C=O)_aO_bC₁-C₁₀ alkyl, 2) (C=O)_aO_baryl, 3) C₂-C₁₀ alkenyl, 4) C₂-C₁₀ alkynyl, 5) (C=O)_aO_b heterocyclyl, 6) (C=O)_aO_bC₃-C₈ cycloalkyl, 7) CO₂H, 8) halo, 9) CN,

10) OH, 11) $\text{O}_b\text{C}_1\text{-C}_6$ perfluoroalkyl, 12) $\text{O}_a(\text{C}=\text{O})_b\text{NR}^6\text{R}^7$, 13) $\text{NR}^c(\text{C}=\text{O})\text{NR}^6\text{R}^7$, 14) $\text{S}(\text{O})_m\text{R}^a$, 15) $\text{S}(\text{O})_2\text{NR}^6\text{R}^7$, 16) $\text{NR}^c\text{S}(\text{O})_m\text{R}^a$, 17) CHO, 18) NO_2 , 19) $\text{NR}^c(\text{C}=\text{O})\text{O}_b\text{R}^a$, 20) $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$ alkyl, 21) $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$ cycloalkyl, 22) $\text{O}(\text{C}=\text{O})\text{O}_b\text{aryl}$, 23) $\text{O}(\text{C}=\text{O})\text{O}_b\text{-heterocycle}$, and 24) $\text{O}_a\text{-P}=\text{O}(\text{OH})_2$, said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R^Z ;

R^3 and R^4 are independently selected from: H, $\text{C}_1\text{-C}_6$ -alkyl and $\text{C}_1\text{-C}_6$ -perfluoroalkyl, or

R^3 and R^4 are combined to form $-(\text{CH}_2)_t-$ wherein one of the carbon atoms is optionally replaced by a moiety selected from O, $\text{S}(\text{O})_m$, $-\text{N}(\text{R}^b)\text{C}(\text{O})-$, and $-\text{N}(\text{COR}^a)-$;

R^5 is independently selected from: 1) $(\text{C}=\text{O})_a\text{O}_b\text{C}_1\text{-C}_{10}$ alkyl, 2) $(\text{C}=\text{O})_a\text{O}_b\text{aryl}$, 3) $\text{C}_2\text{-C}_{10}$ alkenyl, 4) $\text{C}_2\text{-C}_{10}$ alkynyl, 5) $(\text{C}=\text{O})_a\text{O}_b$ heterocyclyl, 6) $(\text{C}=\text{O})_a\text{O}_b\text{C}_3\text{-C}_8$ cycloalkyl, 7) CO_2H , 8) halo, 9) CN, 10) OH, 11) $\text{O}_b\text{C}_1\text{-C}_6$ perfluoroalkyl, 12) $\text{O}_a(\text{C}=\text{O})_b\text{NR}^6\text{R}^7$, 13) $\text{NR}^c(\text{C}=\text{O})\text{NR}^6\text{R}^7$, 14) $\text{S}(\text{O})_m\text{R}^a$, 15) $\text{S}(\text{O})_2\text{NR}^6\text{R}^7$, 16) $\text{NR}^c\text{S}(\text{O})_m\text{R}^a$, 17) oxo, 18) CHO, 19) NO_2 , 20) $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$ alkyl, 21) $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$ cycloalkyl, and 22) $\text{O}_a\text{-P}=\text{O}(\text{OH})_2$, said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R^Z ;

R^6 and R^7 are independently selected from: 1) H, 2) $(\text{C}=\text{O})\text{O}_b\text{R}^a$, 3) $\text{C}_1\text{-C}_{10}$ alkyl, 4) aryl, 5) $\text{C}_2\text{-C}_{10}$ alkenyl, 6) $\text{C}_2\text{-C}_{10}$ alkynyl, 7) heterocyclyl, 8) $\text{C}_3\text{-C}_8$ cycloalkyl, 9) SO_2R^a , 10) $(\text{C}=\text{O})\text{NR}^b$, 11) OH, and 12) $\text{O}_a\text{-P}=\text{O}(\text{OH})_2$, said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^Z , or

R^6 and R^7 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 4-7 members in each ring and optionally containing, in addition to the nitrogen, one or more additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R^Z ;

R^Z is independently selected from: 1) $(\text{C}=\text{O})_r\text{O}_s(\text{C}_1\text{-C}_{10})\text{alkyl}$, 2) $\text{O}_r(\text{C}_1\text{-C}_3)\text{perfluoroalkyl}$, 3) $(\text{C}_0\text{-C}_6)\text{alkylene-S}(\text{O})_m\text{R}^a$, 4) oxo, 5) OH, 6) halo, 7) CN, 8) $(\text{C}=\text{O})_r\text{O}_s(\text{C}_2\text{-C}_{10})\text{alkenyl}$, 9) $(\text{C}=\text{O})_r\text{O}_s(\text{C}_2\text{-C}_{10})\text{alkynyl}$, 10) $(\text{C}=\text{O})_r\text{O}_s(\text{C}_3\text{-C}_6)\text{cycloalkyl}$, 11) $(\text{C}=\text{O})_r\text{O}_s(\text{C}_0\text{-C}_6)\text{alkylene-aryl}$, 12) $(\text{C}=\text{O})_r\text{O}_s(\text{C}_0\text{-C}_6)\text{alkylene-heterocyclyl}$, 13) $(\text{C}=\text{O})_r\text{O}_s(\text{C}_0\text{-C}_6)\text{alkylene-N}(\text{R}^b)_2$, 14) $\text{C}(\text{O})\text{R}^a$, 15) $(\text{C}_0\text{-C}_6)\text{alkylene-CO}_2\text{R}^a$, 16) $\text{C}(\text{O})\text{H}$, 17) $(\text{C}_0\text{-C}_6)\text{alkylene-CO}_2\text{H}$, 18) $\text{C}(\text{O})\text{N}(\text{R}^b)_2$, 19) $\text{S}(\text{O})_m\text{R}^a$, 20) $\text{S}(\text{O})_2\text{N}(\text{R}^b)_2$, 21) $\text{NR}^c(\text{C}=\text{O})\text{O}_b\text{R}^a$, 22) $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$ alkyl, 23) $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$ cycloalkyl, 24) $\text{O}(\text{C}=\text{O})\text{O}_b\text{aryl}$, 25) $\text{O}(\text{C}=\text{O})\text{O}_b\text{-heterocycle}$, and 26) $\text{O}_a\text{-P}=\text{O}(\text{OH})_2$, said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and

heterocyclyl is optionally substituted with up to three substituents selected from R^b , OH, $(C_1-C_6)alkoxy$, halogen, CO_2H , CN, $O(C=O)C_1-C_6$ alkyl, oxo, $N(R^b)_2$ and $O_a-P=O(OH)_2$;


R^a is: substituted or unsubstituted $(C_1-C_6)alkyl$, substituted or unsubstituted $(C_2-C_6)alkenyl$, substituted or unsubstituted $(C_2-C_6)alkynyl$, substituted or unsubstituted $(C_3-C_6)cycloalkyl$, substituted or unsubstituted aryl, $(C_1-C_6)perfluoroalkyl$, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

R^b is: H, $(C_1-C_6)alkyl$, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl, $(C_3-C_6)cycloalkyl$, $(C=O)OC_1-C_6$ alkyl, $(C=O)C_1-C_6$ alkyl or $S(O)_2R^a$;

R^c is selected from: 1) H, 2) C_1-C_{10} alkyl, 3) aryl, 4) C_2-C_{10} alkenyl, 5) C_2-C_{10} alkynyl, 6) heterocyclyl, 7) C_3-C_8 cycloalkyl, and 8) C_1-C_6 perfluoroalkyl, said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^z , or

or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. (previously presented) The compound according to Claim 1 of the Formula B:



or a pharmaceutically acceptable salt or a stereoisomer thereof.

3. (previously presented) The compound according to Claim 2 wherein:

Q is pyrimidinyl pyrazole optionally substituted with one to three R^z ;

R^a is: $(C_1-C_6)alkyl$, $(C_3-C_6)cycloalkyl$, aryl, or heterocyclyl; and

R^b is: H, $(C_1-C_6)alkyl$, aryl, heterocyclyl, $(C_3-C_6)cycloalkyl$, $(C=O)OC_1-C_6alkyl$, $(C=O)C_1-C_6alkyl$ or $S(O)_2R^a$;

or a pharmaceutically acceptable salt or a stereoisomer thereof.


4. (original) The compound according to Claim 3 wherein:

q is 0;

R² is independently selected from: 1) C₁-C₆ alkyl, 2) aryl, 3) heterocyclyl, 4) CO₂H, 5) halo, 6) CN, 7) OH, 8) S(O)₂NR⁶R⁷, and 9) O_a-P=O(OH)₂, said alkyl, aryl and heterocyclyl optionally substituted with one, two or three substituents selected from R^z;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

5. (previously presented) The compound according to Claim 4 of the Formula C:



wherein:

n is 0, 1 or 2;

Q is pyrimidinyl pyrazole optionally substituted with one to three R^z;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

6. (previously presented) A compound which is selected from:

1-(1-{4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-3-phenylpyridin-2-yl]benzyl}piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;

1-(1-{4-[5-(1,2,4-oxadiazol-3-yl)-3-phenylpyridin-2-yl]benzyl}piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;

1-(1-{4-[3-phenyl-5-(1H-1,2,4-triazol-5-yl)pyridin-2-yl]benzyl}piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;

1-{1-[4-(3-phenyl-5-pyrimidin-2-ylpyridin-2-yl)benzyl]piperidin-4-yl}-1H-pyrazolo[3,4-d]pyrimidin-4-amine;


1-{1-[4-(5'-phenyl-2,3'-bipyridin-6'-yl)benzyl]piperidin-4-yl}-1H-pyrazolo[3,4-d]pyrimidin-4-amine;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

7-10. (canceled)

11. (original) A compound according to Claim 6 which is:

1-(1-[4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-3-phenylpyridin-2-yl]benzyl]piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine:




or a pharmaceutically acceptable salt or a stereoisomer thereof.

12. (canceled)

13. (original) A compound according to Claim 6 which is:


1-(1-[4-[5-(1,2,4-oxadiazol-3-yl)-3-phenylpyridin-2-yl]benzyl]piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine:



or a pharmaceutically acceptable salt or a stereoisomer thereof.

14. (original) A compound according to Claim 6 which is:

1-{1-[4-(3-phenyl-5-pyrimidin-2-ylpyridin-2-yl)benzyl]piperidin-4-yl}-1H-pyrazolo[3,4-d]pyrimidin-4-amine;



or a pharmaceutically acceptable salt or a stereoisomer thereof.

15. (original) A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

16. (original) A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 6.

17. (currently amended) A method for treating ~~esophageal~~ carcinoma which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

18. (currently amended) A method for treating ~~esophageal~~ carcinoma which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 6.

19-20. (canceled)